Patents by Inventor Yaron R. Hadari

Yaron R. Hadari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the Treatment of Fibrotic Disease
    Publication number: 20240124483
    Abstract: Provided herein are methods and corresponding compounds for treating fibrotic disease by administering to a subject a compound of Formula I or pharmaceutically acceptable salt thereof, which inhibits phosphorylation of Smad2/3, according to Phospho-Smad2/3 Inhibition Assay, including compounds that are active according to MAPK p38 Activation Assay; or a compound of Formula II or III. Also provided are methods and corresponding compounds for treating cancers, inflammatory diseases, rasopathies and autoimmune leukoproliferative disorders.
    Type: Application
    Filed: January 27, 2022
    Publication date: April 18, 2024
    Inventors: Yaron R. Hadari, Michael Schmertzler, Theresa M. Williams, Luca Carta, Rebecca Hutcheson
  • Compounds for the Treatment of Cancer and Inflammatory Disease
    Publication number: 20230286997
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Application
    Filed: October 28, 2022
    Publication date: September 14, 2023
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
    Publication number: 20230227466
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.
    Type: Application
    Filed: June 17, 2021
    Publication date: July 20, 2023
    Inventors: Yaron R. Hadari, Michael Schmertzler, Theresa M. Williams, Luca Carta, Rebecca Hutcheson
  • Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
    Publication number: 20230149369
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Application
    Filed: June 28, 2022
    Publication date: May 18, 2023
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
    Publication number: 20230078755
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.
    Type: Application
    Filed: December 18, 2019
    Publication date: March 16, 2023
    Inventors: Yaron R. Hadari, Michael Schmertzler, Theresa M. Williams, Luca Carta, Rebecca Hutcheson, Charles H. Reynolds
  • Compounds for the treatment of cancer and inflammatory disease
    Patent number: 11560390
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 24, 2023
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
    Patent number: 11541041
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 3, 2023
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
    Publication number: 20220347162
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Application
    Filed: January 6, 2021
    Publication date: November 3, 2022
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
    Publication number: 20220332725
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Application
    Filed: September 16, 2020
    Publication date: October 20, 2022
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11213515
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 4, 2022
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11026930
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: June 8, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11000515
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 11, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10940139
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10933054
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 2, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds for the treatment of cancer and inflammatory disease
    Patent number: 10870657
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 22, 2020
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
    Publication number: 20200121660
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10588894
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 17, 2020
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
    Publication number: 20200061037
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 27, 2020
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
    Publication number: 20200054614
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 20, 2020
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE
    Publication number: 20190218229
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds